Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
$11.74
$10.00
$3.47
$12.43
$1.78B1.831.63 million shs1.67 million shs
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
$32.75
+1.6%
$33.33
$26.47
$41.61
$1.85B0.83633,949 shs1.06 million shs
Organogenesis stock logo
ORGO
Organogenesis
$4.63
+8.9%
$3.55
$2.28
$6.71
$539.13M1.71.16 million shs1.15 million shs
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
$16.95
-0.8%
$14.97
$8.91
$18.90
$1.68B0.91.35 million shs1.30 million shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
-1.97%+0.77%+16.35%+53.26%+231.64%
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
+0.47%+2.03%-9.44%+14.61%+1.45%
Organogenesis stock logo
ORGO
Organogenesis
-2.30%+16.12%+40.26%+14.86%+52.88%
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
+3.67%-2.06%+17.94%+38.61%+87.80%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
3.4203 of 5 stars
1.43.00.04.23.02.50.6
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
4.8289 of 5 stars
4.61.00.00.03.33.34.4
Organogenesis stock logo
ORGO
Organogenesis
4.3376 of 5 stars
3.03.00.04.31.94.20.6
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
3.2421 of 5 stars
3.61.00.00.03.24.20.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
2.86
Moderate Buy$10.57-9.95% Downside
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
3.13
Buy$53.6363.74% Upside
Organogenesis stock logo
ORGO
Organogenesis
2.00
Hold$6.0029.59% Upside
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
3.17
Buy$31.0082.89% Upside

Current Analyst Ratings Breakdown

Latest ORGO, HRMY, ADPT, and SPRY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/18/2025
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$15.00
6/2/2025
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$61.00
5/15/2025
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$44.00 ➝ $48.00
5/13/2025
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/6/2025
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$11.00 ➝ $13.00
5/6/2025
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$49.00 ➝ $49.00
5/5/2025
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$7.00 ➝ $9.00
5/2/2025
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$9.00 ➝ $10.00
4/28/2025
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$55.00 ➝ $48.00
4/8/2025
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$70.00 ➝ $70.00
4/8/2025
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00 ➝ $50.00
(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
$178.96M9.97N/AN/A$1.37 per share8.57
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
$714.73M2.63$2.99 per share10.94$11.56 per share2.83
Organogenesis stock logo
ORGO
Organogenesis
$482.04M1.22$0.23 per share20.37$2.09 per share2.22
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
$89.15M18.67$0.01 per share2,018.11$2.64 per share6.42
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
-$159.49M-$0.96N/AN/AN/A-74.84%-62.79%-24.55%7/30/2025 (Estimated)
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
$145.49M$2.6212.5010.530.4820.53%24.32%15.92%8/5/2025 (Estimated)
Organogenesis stock logo
ORGO
Organogenesis
$860K-$0.17N/AN/AN/A-3.46%-4.00%-2.26%8/6/2025 (Estimated)
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
$8M-$0.16N/AN/AN/A-16.11%-6.94%-5.60%8/5/2025 (Estimated)

Latest ORGO, HRMY, ADPT, and SPRY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
$0.78N/AN/AN/A$204.37 millionN/A
8/5/2025Q2 2025
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
-$0.42N/AN/AN/A$12.92 millionN/A
5/14/2025Q1 2025
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
-$0.35-$0.35N/A-$0.35$7.48 million$7.97 million
5/8/2025Q1 2025
Organogenesis stock logo
ORGO
Organogenesis
$0.04-$0.13-$0.17-$0.17$90.77 million$86.69 million
5/6/2025Q1 2025
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
$0.59$0.78+$0.19$0.78$184.26 million$184.73 million
5/1/2025Q1 2025
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
-$0.28-$0.20+$0.08-$0.20$42.13 million$52.44 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
N/AN/AN/AN/AN/A
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
N/AN/AN/AN/AN/A
Organogenesis stock logo
ORGO
Organogenesis
N/AN/AN/AN/AN/A
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
N/A
2.92
2.82
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
0.22
3.67
3.63
Organogenesis stock logo
ORGO
Organogenesis
N/A
4.12
3.67
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
0.30
11.00
10.74

Institutional Ownership

CompanyInstitutional Ownership
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
99.17%
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
86.23%
Organogenesis stock logo
ORGO
Organogenesis
49.57%
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
68.16%

Insider Ownership

CompanyInsider Ownership
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
6.40%
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
23.60%
Organogenesis stock logo
ORGO
Organogenesis
33.00%
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
33.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Adaptive Biotechnologies Corporation stock logo
ADPT
Adaptive Biotechnologies
790151.92 million142.19 millionOptionable
Harmony Biosciences Holdings, Inc. stock logo
HRMY
Harmony Biosciences
20057.42 million43.87 millionOptionable
Organogenesis stock logo
ORGO
Organogenesis
950126.85 million84.99 millionOptionable
ARS Pharmaceuticals, Inc. stock logo
SPRY
ARS Pharmaceuticals
9098.21 million65.31 millionOptionable

Recent News About These Companies

Brokers Offer Predictions for SPRY FY2029 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Adaptive Biotechnologies stock logo

Adaptive Biotechnologies NASDAQ:ADPT

$11.74 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$11.88 +0.15 (+1.24%)
As of 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Harmony Biosciences stock logo

Harmony Biosciences NASDAQ:HRMY

$32.75 +0.51 (+1.58%)
As of 04:00 PM Eastern

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Organogenesis stock logo

Organogenesis NASDAQ:ORGO

$4.63 +0.38 (+8.94%)
Closing price 04:00 PM Eastern
Extended Trading
$4.76 +0.13 (+2.81%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

ARS Pharmaceuticals stock logo

ARS Pharmaceuticals NASDAQ:SPRY

$16.95 -0.14 (-0.82%)
Closing price 04:00 PM Eastern
Extended Trading
$16.94 -0.01 (-0.06%)
As of 04:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.